Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma

This study is testing whether delivering immunotherapy drugs (checkpoint inhibitors like PD-1/PD-L1/CTLA-4 blockers) directly into the liver artery — rather than through a standard IV infusion — is more effective for treating hepatocellular carcinoma (the most common type of liver cancer). Direct delivery may increase the concentration of the drug at the tumor site. **You may be eligible if...** - You have a confirmed diagnosis of liver cancer (hepatocellular carcinoma) - You are between 18 and 80 years old with an estimated survival of more than 3 months - Your liver function is in acceptable range (Child-Pugh class A or B) - You are in reasonably good physical condition (ECOG score under 2) - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have serious blood clotting problems that cannot be corrected - You have severe liver failure - You have active autoimmune disease - You are pregnant or breastfeeding - You have widespread cancer spread to many organs Talk to your doctor to see if this trial is right for you.